DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0088056A1 Ye Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 20140O88056A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0088056A1 Ye et al. (43) Pub. Date: Mar. 27, 2014 (54) CARDIAC GLYCOSIDES ARE POTENT Publication Classification INHIBITORS OF INTERFERON-BETA GENE EXPRESSION (51) Int. Cl. A613 L/585 (2006.01) A 6LX3/59 (2006.01) (75) Inventors: Junqiang Ye, Fort Lee, NJ (US); A613 L/7 (2006.01) Shuibing Chen, Pelham, NY (US); Tom A 6LX3 L/505 (2006.01) Maniatis, New York, NY (US) A613 L/407 (2006.01) A63L/36 (2006.01) (52) U.S. Cl. (73) Assignee: PRESIDENT AND FELLOWS OF CPC ............. A6 IK3I/585 (2013.01); A61 K3I/407 HARVARD COLLEGE, Cambridge, (2013.01); A61 K3I/136 (2013.01); A61 K MA (US) 3 1/17 (2013.01); A61K3I/505 (2013.01); A6 IK3I/519 (2013.01) (21) Appl. No.: 13/876,795 USPC ........... 514/175: 514/410; 514/656; 514/597; (22) PCT Filed: Sep. 28, 2011 514/256; 514/264.11: 435/375; 435/184 (57) ABSTRACT (86). PCT No.: The invention provides for a method of inhibiting interferon S371 (c)(1), beta gene expression and/or reducing the level of interferon (2), (4) Date: Nov. 25, 2013 beta in a cell by contacting the cell with a Na", Ca", or K" ion-channel modulator. The invention also provides for a method of treating a disease or disorder characterized by Related U.S. Application Data elevated interferon beta levels or elevated levels of interferon (60) Provisional application No. 61/387,407, filed on Sep. beta gene expression. Additionally, the invention provides a 28, 2010. method for treating pathogenic or non-pathogenic infections. Patent Application Publication Mar. 27, 2014 Sheet 1 of 30 US 2014/0088056A1 Se 5 5. FIG. IA N ,- Se r E r t e s 8F s -- e -- as -- PR) PR3 R FIG. IB Patent Application Publication Mar. 27, 2014 Sheet 2 of 30 US 2014/0088056A1 PPPRSA Pip NFRSF2A EP CRS FS F3 RASSF S25.25 CK Si SP I3 PE8 RC 835 E3322 F393 CPA R839 RBS CSR. 3. AR R8 EA3 R PPR SR56 CRE8 BRS S Cliff EY Siii. F8 C38 G5 BSS PK Fi S3 iGF SPSB CEBP R i-8 Patent Application Publication Mar. 27, 2014 Sheet 3 of 30 US 2014/0088056A1 E pa al F Cxc ES5 CC FI 8 RG AS PPPRA OGP1 NS P Cited PRB4 PR6 ES S. Sey-NP Se GAPDH FIG. ID CRO POYC POY it BFA - . - - o -- FIG, IE Patent Application Publication Mar. 27, 2014 Sheet 4 of 30 US 2014/0088056A1 5 t E s i S s se ce a. NS & % Šs. % Patent Application Publication Mar. 27, 2014 Sheet 5 of 30 US 2014/0088056A1 Se FOR 15 RS CANE) Eji - "...". BFN REAE) . w FIG. 2E Bis BFA - - - -- NP) BON-SA BFN - Patent Application Publication Mar. 27, 2014 Sheet 6 of 30 US 2014/0088056A1 Ridds PE isRNA 3.5- as 3 S 2.5 2 s: 1.3 S.S ?h, re dsRNA + - - - - - - -- NaCl) . 38 OB 2.0 . RG-APaseoKCM. 30 00 200 Patent Application Publication Mar. 27, 2014 Sheet 7 of 30 US 2014/0088056A1 s 3.is Lu- isES 1. ; 2. 2 : F- - - - S 8 - -- Na+- BFA FIG. 3C Patent Application Publication Mar. 27, 2014 Sheet 8 of 30 US 2014/0088056A1 APa O 18. 29 i SSSF.C.is 8,rt, EEERNISific, Si WW iSE & I.S. f v. APa3 s 8 S 3 SE S.S.S.S.C.S.&S* , , , 's i.fi'8' xi. ESS): Y ESGISN.S fish, S. S. .. .x . if. R alala FIG. 4A N Se , 8 8 2 -- " - - - BUFALN - - - - - - - - - - - it SCOR Bia a SP33 FIG. 4B Patent Application Publication Mar. 27, 2014 Sheet 9 of 30 US 2014/0088056A1 N Se 8 f BUFALN - " - f. - - - BiPai Ripa 38 FIG. 4C N "Se Patent Application Publication Mar. 27, 2014 Sheet 10 of 30 US 2014/0088056A1 Pa ACN FIG. 5A 3. AN Fi 83 . 8,883 Se Act Se did CNR AP3 C, FIG. 5B Patent Application Publication Mar. 27, 2014 Sheet 11 of 30 US 2014/0088056A1 88 ACXCO 0.07 a 0.86 3 (.85 E 8.04 0.3 is 0.02 0.01 8 Se Aid T S Atti CR APa (NCK); FIG. 5C sh SCRABE AP NCER - Se C did - Se Eid FIG. 5D Patent Application Publication Mar. 27, 2014 Sheet 12 of 30 US 2014/0088056A1 8.84. OSE FN 8.835 a .830 (.625 E 0.020 if (5 0.018 9,005 ce ) Set i di Se iC At CONR) A Pa KNOCK FIG. 5E 3. SECC 2.5 2 2. E 1.5 10 is 8.5 to 8,8- F-fil Se : ; Se is tid COTR A Pa KNCK FIG. 5F Patent Application Publication Mar. 27, 2014 Sheet 13 of 30 US 2014/0088056A1 RSE RF til sts 8. 3. 3 8 E 8,006 Ea.004 E. is 8,902 ce 888 SetSe it dAid Sey C Ad CR Pai (NCK); FIG. 5G SCRAB, SCRABE-Sey &SCRAS-C SSCRABE-At SAP: 8Pai Se SAPai 88 Pai-it SRNA SCRARBE AIPlai SCRAABE APa SCRAYBE AFPla Stat rex RG FIG. 5H Patent Application Publication Mar. 27, 2014 Sheet 14 of 30 US 2014/0088056A1 e t N : (O9(5)IAI C19º?I,HI ######8- {{9(9.I.H. text ran we be in a w tes S8338 Patent Application Publication Mar. 27, 2014 Sheet 15 of 30 US 2014/0088056A1 B Set - - r FIG, 7B Patent Application Publication Mar. 27, 2014 Sheet 16 of 30 US 2014/0088056A1 Se - - - -- BFN - - - -- R3 ER RONGREER BFN Se : Ad - Se is did FN GAP FIG. 7D i Patent Application Publication Mar. 27, 2014 Sheet 17 of 30 US 2014/0088056A1 8 Se is .8 S , CNR 8 8 FIG. 8A 3 IN IS 2.5 C 2 5 E 8,3 i ri rii - CR ti O BF FIG. 8B Patent Application Publication Mar. 27, 2014 Sheet 18 of 30 US 2014/0088056A1 NCR AXE NOPINE PENA Se - - a - bh - FN C RG Sey NP GAPDH FIG. 9 Se C did BUFALN w v. FIG 10A Patent Application Publication Mar. 27, 2014 Sheet 19 of 30 US 2014/0088056A1 SCRAMBLE shRNA Pai siRNA F. FIG. 10B NNER Sey C dard BFA - -- al -- Wax -- sh -- Patent Application Publication Mar. 27, 2014 Sheet 20 of 30 US 2014/0088056A1 293 S3 - BFAN Fa 3 S 5 30 S Ba pKBa p-S276 p53 p-S468 p$5 p$536 pg5 staf bACTIN FIG. I2B Patent Application Publication Mar. 27, 2014 Sheet 21 of 30 US 2014/0088056A1 SSy se s Se:E YS san see N s Sa & > s s: Sis wnsS ar Q geS is Ns - is war era is a ti e if ge Y re s' s 8Se. i i. s -9 - ON s assar Patent Application Publication Mar. 27, 2014 Sheet 22 of 30 US 2014/0088056A1 FULL LENGTH (CEAVED ARP EAE PRP EAE) CSPSE3 FIG. 14A PARP shRNA Pa SR Se Ai - Se it FIG. 14B Patent Application Publication Mar. 27, 2014 Sheet 23 of 30 US 2014/0088056A1 BFA Exc RG Stati SG AP FIG. 15A CNR) PS BN FIG. 15B EGF BFA - - - x p-P42/44 P42s. FIG. 15C Patent Application Publication Mar. 27, 2014 Sheet 24 of 30 US 2014/0088056A1 i8 358 38 5 2688. 388 3 38 - - UNTREATED int. Only 10Bay it. Of Bt FIG. 16A s UNTREATED inly Only 100nM M 10M BFA FIG. 16B Patent Application Publication Mar. 27, 2014 Sheet 25 of 30 US 2014/0088056A1 F E"ENG PARP EAE PARP EE ASPASE3 FIG. 16D Patent Application Publication Mar. 27, 2014 Sheet 26 of 30 US 2014/0088056A1 YNSp 8 NGSp 8 3. s as a. Seea an i se c c c is as E s s w- re al s . e 'asad E . re E e 8 is QSs r N E s s -: QSN N (ONSN Patent Application Publication Mar. 27, 2014 Sheet 27 of 30 US 2014/0088056A1 8I’0IJI Patent Application Publication Mar. 27, 2014 Sheet 28 of 30 US 2014/0088056A1 CRO. Se BF ER RF3 ONER AP 283, shRNA FIG. 19A P BN-tisNA BFA -- - - 8 FIG. 19C Patent Application Publication Mar. 27, 2014 Sheet 29 of 30 US 2014/0088056A1 SRNA SCRA 8.E. t NCER . Sey did Setti Aid FIG. 19D CNR FA 28 3 is i 8 3 88 24 : KBa FIG. I9E Patent Application Publication Mar. 27, 2014 Sheet 30 of 30 US 2014/0088056A1 SAFE XC s 151 as in g|MOUSE EFFECES OF BFAN N A Pa KNOCK-NEESRYA FIG. 20A IBF "S) . 23 28 3. l 68 $ii HOURS POSLPS INECTION (80 mg/kg) FIG. 20B US 2014/0088056A1 Mar. 27, 2014 CARDAC GLYCOSDES ARE POTENT Rosen, A. Type I interferons: crucial participants in disease INHIBITORS OF INTERFERON-BETA GENE amplification in autoimmunity. Nat Rev Rheumatol 6, 40-9. EXPRESSION Overproduction of interferon has been recognized as the major cause of systemic lupus erythematosus (SLE) RELATED APPLICATIONS (Banchereau, J. & Pascual, V. Type I interferon in systemic 0001. This application claims benefit under 35 U.S.C. lupus erythematosus and other autoimmune diseases. Immu S119(e) of the U.S. Provisional Application No. 61/387,407, nity 25, 383-92 (2006)). In addition, strong innate immune filed Sep. 28, 2010, content of which is incorporated herein by responses (including IFN production) have been shown to reference in its entirety. contribute to AIDS virus infection (Mandl, J. N. et al.
Recommended publications
  • Bufadienolides from the Skin Secretions of the Neotropical Toad Rhinella Alata (Anura: Bufonidae): Antiprotozoal Activity Against Trypanosoma Cruzi

    Bufadienolides from the Skin Secretions of the Neotropical Toad Rhinella Alata (Anura: Bufonidae): Antiprotozoal Activity Against Trypanosoma Cruzi

    molecules Article Bufadienolides from the Skin Secretions of the Neotropical Toad Rhinella alata (Anura: Bufonidae): Antiprotozoal Activity against Trypanosoma cruzi Candelario Rodriguez 1,2,3 , Roberto Ibáñez 4 , Luis Mojica 5, Michelle Ng 6, Carmenza Spadafora 6 , Armando A. Durant-Archibold 1,3,* and Marcelino Gutiérrez 1,* 1 Centro de Biodiversidad y Descubrimiento de Drogas, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Apartado 0843-01103, Panama; [email protected] 2 Department of Biotechnology, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur 522510, India 3 Departamento de Bioquímica, Facultad de Ciencias Naturales, Exactas y Tecnología, Universidad de Panamá, Apartado 0824-03366, Panama 4 Smithsonian Tropical Research Institute (STRI), Balboa, Ancon P.O. Box 0843-03092, Panama; [email protected] 5 Centro Nacional de Metrología de Panamá (CENAMEP AIP), Apartado 0843-01353, Panama; [email protected] 6 Centro de Biología Celular y Molecular de Enfermedades, INDICASAT AIP, Apartado 0843-01103, Panama; [email protected] (M.N.); [email protected] (C.S.) * Correspondence: [email protected] (A.A.D.-A.); [email protected] (M.G.) Abstract: Toads in the family Bufonidae contain bufadienolides in their venom, which are charac- Citation: Rodriguez, C.; Ibáñez, R.; terized by their chemical diversity and high pharmacological potential. American trypanosomiasis Mojica, L.; Ng, M.; Spadafora, C.; is a neglected disease that affects an estimated 8 million people in tropical and subtropical coun- Durant-Archibold, A.A.; Gutiérrez, M. tries. In this research, we investigated the chemical composition and antitrypanosomal activity Bufadienolides from the Skin of toad venom from Rhinella alata collected in Panama.
  • The Immune-Adherence Activity of Normal Sera with Respect to Certain Particulate Antigens

    The Immune-Adherence Activity of Normal Sera with Respect to Certain Particulate Antigens

    Vol. XL, No. 1 (February, 1959), wasised on 13.2.59. THE BRITISH JONAL OF EXPERIMENTAL PATHOLOGY VOL. XL APRIL, 1959 NO. 2 THE IMMUNE-ADHERENCE ACTIVITY OF NORMAL SERUM J. L. TURK From the London School of Hygiene and Tropical Medicine, Keppel Street, London, W.C.1 Received for publication August 22, 1958 A HEAT labile non-specific complement-fixing activity in normal serum was described by Mackie and Finkelstein (1930). A similar activity was described by Pillemer et al. (1954) which they called the properdin system. That part of the properdin system which is absorbed by zymosan and a wide range of poly- saccharides has been shown to account for some of the bactericidal and viricidal activity of normal serum (Pillemer et al., 1954 and 1955). Properdin appears to need Mg+ + ions and serum co-factors resembling the 4 components of comple- ment for its action. The immune-adherence phenomenon (Nelson, 1953), in which an antigen coated with its specific antibody and after fixing all 4 components of complement will adhere to the primate red cell, provides a sensitive test with which to re- explore the immunological activity of normal sera. Antibody to particulate antigens can be titrated by counting the numbers of red cells with adherent antigens, in immune-adherence reaction mixtures, under the phase contrast microscope. Nelson and Lebrun (1956) found that normal guinea-pig serum caused the immune-adherence of starch grains and Nelson and Kelsey (personal communi- cation) found the same true for zymosan. The present work describes the immune-adherence activity of normal sera with respect to certain particulate antigens.
  • Holocene Environmental Changes Disclosed from Anoxic Fjord Sediments by Biomarkers and Their Radiocarbon Content

    Holocene Environmental Changes Disclosed from Anoxic Fjord Sediments by Biomarkers and Their Radiocarbon Content

    GEOLOGICA ULTRAIECTINA Mededelingen van de Faculteit Geowetenschappen Universiteit Utrecht No. 227 Holocene environmental changes disclosed from anoxic fjord sediments by biomarkers and their radiocarbon content Rienk H. Smittenberg Holocene environmental changes disclosed from anoxic fjord sediments by biomarkers and their radiocarbon content Holocene milieuveranderingen gereconstrueerd uit anoxische fjord sedimenten middels biomarkers en hun radio-aktief koolstof gehalte (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de Rector Magnificus, Prof. Dr. W.H. Gispen, ingevolge het besluit van het College voor Promoties in het openbaar te verdedigen op maandag 15 september 2003 des middags te 4.15 uur door Rienk Hajo Smittenberg geboren op 23 maart 1973 te Eck en Wiel Promotor: Prof. Dr. J.W. de Leeuw Department of Geochemistry Utrecht University Utrecht, The Netherlands Copromotores: Dr. Ir. J.S. Sinninghe Damsté Department of Geochemistry Utrecht University Utrecht, The Netherlands Dr. S. Schouten Department of Marine Biogeochemistry and Toxicology Royal Netherlands Institute of Sea Research Texel, The Netherlands The research described in this thesis was carried out at the Department of Biogeochemistry and Toxicology of the Royal Netherlands Institute of Sea Research, P.O. Box 59, 1790 AB Den Burg, The Netherlands. The investigations were supported by the Research Council for Earth and Life Science (ALW) with the financial support from the Netherlands
  • Application of Biomarker Compounds As Tracers for Sources and Fates of Natural and Anthropogenic Organic Matter in Tile Environment

    Application of Biomarker Compounds As Tracers for Sources and Fates of Natural and Anthropogenic Organic Matter in Tile Environment

    AN ABSTRACT OF THE DISSERTATION OF Daniel R. Oros for the degree of Doctor of Philosophy in Environmental Sciences presented on September 24. 1999. Title: Application of Biomarker Compoundsas Tracers for Sources and Fates of Natural and Anthropogenic Organic Matter in the Environment. Redacted for Privacy Abstract approved: Bernd R.T. Simoneit Determination of the source and fate of natural (higher plant lipids, marine lipids, etc.) and anthropogenically (e.g., petroleum, coal emissions) derived hydrocarbons and oxygenated compounds in the environment was accomplished using gas chromatography (GC) and gas chromatography-mass spectrometry (GC- MS) to characterize or identify molecular biomarkers to be utilized as tracers. The distributions and abundances of biomarkers such as straight chain homologous series (e.g., n-alkanes, n-alkanoic acids, n-alkan-2-ones, n-alkanols, etc.) and cyclic terpenoid compounds (e.g., sesquiterpenoids, diterpenoids, steroids, triterpenoids) were identified in epicuticular waxes from conifers of western North America (natural emissions). These biomarkers and their thermal alteration derivativeswere also identified in smoke emissions from known vegetation sources (e.g., conifers, deciduous trees and grasses) and were then applied as tracers in soils, soils that contained wildfire residues and soillriver mud washout after wildfire burning. Where possible, the reaction pathways of transformation from the parentprecursor compounds to intermediate and final alteration products were determined from GC- MS data. In addition, molecular tracer analysis was applied to air, water and sediment samples collected from a lacustrine setting (Crater Lake, OR) in order to determine the identities, levels and fates of anthropogenic (i.e., petroleum hydrocarbon contamination from boating and related activities) hydrocarbons ina pristine organic matter sink.
  • Biological Toxins Fact Sheet

    Biological Toxins Fact Sheet

    Work with FACT SHEET Biological Toxins The University of Utah Institutional Biosafety Committee (IBC) reviews registrations for work with, possession of, use of, and transfer of acute biological toxins (mammalian LD50 <100 µg/kg body weight) or toxins that fall under the Federal Select Agent Guidelines, as well as the organisms, both natural and recombinant, which produce these toxins Toxins Requiring IBC Registration Laboratory Practices Guidelines for working with biological toxins can be found The following toxins require registration with the IBC. The list in Appendix I of the Biosafety in Microbiological and is not comprehensive. Any toxin with an LD50 greater than 100 µg/kg body weight, or on the select agent list requires Biomedical Laboratories registration. Principal investigators should confirm whether or (http://www.cdc.gov/biosafety/publications/bmbl5/i not the toxins they propose to work with require IBC ndex.htm). These are summarized below. registration by contacting the OEHS Biosafety Officer at [email protected] or 801-581-6590. Routine operations with dilute toxin solutions are Abrin conducted using Biosafety Level 2 (BSL2) practices and Aflatoxin these must be detailed in the IBC protocol and will be Bacillus anthracis edema factor verified during the inspection by OEHS staff prior to IBC Bacillus anthracis lethal toxin Botulinum neurotoxins approval. BSL2 Inspection checklists can be found here Brevetoxin (http://oehs.utah.edu/research-safety/biosafety/ Cholera toxin biosafety-laboratory-audits). All personnel working with Clostridium difficile toxin biological toxins or accessing a toxin laboratory must be Clostridium perfringens toxins Conotoxins trained in the theory and practice of the toxins to be used, Dendrotoxin (DTX) with special emphasis on the nature of the hazards Diacetoxyscirpenol (DAS) associated with laboratory operations and should be Diphtheria toxin familiar with the signs and symptoms of toxin exposure.
  • Animal Venom Derived Toxins Are Novel Analgesics for Treatment Of

    Animal Venom Derived Toxins Are Novel Analgesics for Treatment Of

    Short Communication iMedPub Journals 2018 www.imedpub.com Journal of Molecular Sciences Vol.2 No.1:6 Animal Venom Derived Toxins are Novel Upadhyay RK* Analgesics for Treatment of Arthritis Department of Zoology, DDU Gorakhpur University, Gorakhpur, UP, India Abstract *Corresponding authors: Ravi Kant Upadhyay Present review article explains use of animal venom derived toxins as analgesics of the treatment of chronic pain and inflammation occurs in arthritis. It is a [email protected] progressive degenerative joint disease that put major impact on joint function and quality of life. Patients face prolonged inappropriate inflammatory responses and bone erosion. Longer persistent chronic pain is a complex and debilitating Department of Zoology, DDU Gorakhpur condition associated with a large personal, mental, physical and socioeconomic University, Gorakhpur, UttarPradesh, India. burden. However, for mitigation of inflammation and sever pain in joints synthetic analgesics are used to provide quick relief from pain but they impose many long Tel: 9838448495 term side effects. Venom toxins showed high affinity to voltage gated channels, and pain receptors. These are strong inhibitors of ion channels which enable them as potential therapeutic agents for the treatment of pain. Present article Citation: Upadhyay RK (2018) Animal Venom emphasizes development of a new class of analgesic agents in form of venom Derived Toxins are Novel Analgesics for derived toxins for the treatment of arthritis. Treatment of Arthritis. J Mol Sci. Vol.2 No.1:6 Keywords: Analgesics; Venom toxins; Ion channels; Channel inhibitors; Pain; Inflammation Received: February 04, 2018; Accepted: March 12, 2018; Published: March 19, 2018 Introduction such as the back, spine, and pelvis.
  • Title the Chemistry on Diterpenoids in 1965 Author(S)

    Title the Chemistry on Diterpenoids in 1965 Author(S)

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Kyoto University Research Information Repository Title The Chemistry on Diterpenoids in 1965 Author(s) Fujita, Eiichi Bulletin of the Institute for Chemical Research, Kyoto Citation University (1966), 44(3): 239-272 Issue Date 1966-10-31 URL http://hdl.handle.net/2433/76121 Right Type Departmental Bulletin Paper Textversion publisher Kyoto University The Chemistry on Diterpenoids in 1965 Eiichi FuJITA* (FujitaLaboratory) ReceivedJune 20, 1966 I. INTRODUCTION Several reviews on diterpenoids have been published.*2 Last year, the author described the chemistry on diterpenoids in 1964 in outline.'7 The present review is concerned with the chemical works on diterpenoids in 1965. The classification consists of abietanes, pimaranes, labdanes, phyllocladanes, gibbanes, diterpene alkaloids, and the others. 1617 151613 2016 2©' 10gII 14 56.7 4®20 I20ei317115118 191 1819 14]5 18 19 AbietanePimaraneLabdane 20its1744a 13 4U15 36 15, 2.®7 110 ®® 18 199 8 PhyllocladaneGibbane II. ABIETANE AND ITS REOATED SKELETONS Lawrence et al.27 isolated palustric acid (2) from gum rosin. The selective crystallization of its 2,6-dimethylpiperidine salt, which precipitated from acetone solution of the rosin, from methanolacetone (1:1) was effective for isolation. The four conjugated dienic resin acids, namely, levopimaric (1), palustric (2), neoabietic (3), and abietic acid (4) were treated with an excess of potassium t- butoxide in dimethyl slufoxide solution at reflux temperature (189°) for 2 minutes.37 All four solutions then exhibited a single major peak in their U.V. spectra charac- teristic of abietic acid.
  • Toxicology in Antiquity

    Toxicology in Antiquity

    TOXICOLOGY IN ANTIQUITY Other published books in the History of Toxicology and Environmental Health series Wexler, History of Toxicology and Environmental Health: Toxicology in Antiquity, Volume I, May 2014, 978-0-12-800045-8 Wexler, History of Toxicology and Environmental Health: Toxicology in Antiquity, Volume II, September 2014, 978-0-12-801506-3 Wexler, Toxicology in the Middle Ages and Renaissance, March 2017, 978-0-12-809554-6 Bobst, History of Risk Assessment in Toxicology, October 2017, 978-0-12-809532-4 Balls, et al., The History of Alternative Test Methods in Toxicology, October 2018, 978-0-12-813697-3 TOXICOLOGY IN ANTIQUITY SECOND EDITION Edited by PHILIP WEXLER Retired, National Library of Medicine’s (NLM) Toxicology and Environmental Health Information Program, Bethesda, MD, USA Academic Press is an imprint of Elsevier 125 London Wall, London EC2Y 5AS, United Kingdom 525 B Street, Suite 1650, San Diego, CA 92101, United States 50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom Copyright r 2019 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions. This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).
  • WO 2012/077038 Al 14 June 20 12 ( 14.06.20 12) W P O P C T

    WO 2012/077038 Al 14 June 20 12 ( 14.06.20 12) W P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/077038 Al 14 June 20 12 ( 14.06.20 12) W P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A21D 13/00 (2006.01) A23L 1/29 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, A21D 13/08 (2006.01) A23L 1/30 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A23C 9/13 (2006.01) HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/IB201 1/055462 OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (22) International Filing Date: SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 5 December 201 1 (05.12.201 1) TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, 61/419,885 6 December 2010 (06.
  • Slow Inactivation in Voltage Gated Potassium Channels Is Insensitive to the Binding of Pore Occluding Peptide Toxins

    Slow Inactivation in Voltage Gated Potassium Channels Is Insensitive to the Binding of Pore Occluding Peptide Toxins

    Biophysical Journal Volume 89 August 2005 1009–1019 1009 Slow Inactivation in Voltage Gated Potassium Channels Is Insensitive to the Binding of Pore Occluding Peptide Toxins Carolina Oliva, Vivian Gonza´lez, and David Naranjo Centro de Neurociencias de Valparaı´so, Facultad de Ciencias, Universidad de Valparaı´so, Valparaı´so, Chile ABSTRACT Voltage gated potassium channels open and inactivate in response to changes of the voltage across the membrane. After removal of the fast N-type inactivation, voltage gated Shaker K-channels (Shaker-IR) are still able to inactivate through a poorly understood closure of the ion conduction pore. This, usually slower, inactivation shares with binding of pore occluding peptide toxin two important features: i), both are sensitive to the occupancy of the pore by permeant ions or tetraethylammonium, and ii), both are critically affected by point mutations in the external vestibule. Thus, mutual interference between these two processes is expected. To explore the extent of the conformational change involved in Shaker slow inactivation, we estimated the energetic impact of such interference. We used kÿconotoxin-PVIIA (kÿPVIIA) and charybdotoxin (CTX) peptides that occlude the pore of Shaker K-channels with a simple 1:1 stoichiometry and with kinetics 100-fold faster than that of slow inactivation. Because inactivation appears functionally different between outside-out patches and whole oocytes, we also compared the toxin effect on inactivation with these two techniques. Surprisingly, the rate of macroscopic inactivation and the rate of recovery, regardless of the technique used, were toxin insensitive. We also found that the fraction of inactivated channels at equilibrium remained unchanged at saturating kÿPVIIA.
  • Download Download

    Download Download

    Revista de Biología Tropical, ISSN: 2215-2075, Vol. 69(2): 545-556, April-June 2021 (Published Apr. 19, 2021) 545 Rostelato-Ferreira, S., Vettorazzo, O.B., Tribuiani, N., Leal, A.P., Dal Belo, C.A., Rodrigues-Simioni, L., Floriano, R.S., Oshima- Franco, Y. (2021). Action of heparin and acetylcholine modulators on the neurotoxicity of the toad Rhinella schneideri (Anura: Bufonidae) in Brazil. Revista de Biología Tropical, 69(2), 545- 556. DOI 10.15517/rbt.v69i2.44539 DOI 10.15517/rbt.v69i2.44539 Action of heparin and acetylcholine modulators on the neurotoxicity of the toad Rhinella schneideri (Anura: Bufonidae) in Brazil Sandro Rostelato-Ferreira1,2; Orcid: 0000-0002-8987-434X Orlando B. Vettorazzo2; Orcid: 0000-0003-4731-4771 Natália Tribuiani2; Orcid: 0000-0002-7661-475X Allan P. Leal3; Orcid: 0000-0002-4689-4615 Cháriston A. Dal Belo3,4; Orcid: 0000-0001-7010-650 Léa Rodrigues-Simioni5; Orcid: 0000-0002-8712-6639 Rafael S. Floriano6; Orcid: 0000-0003-0759-5863 Yoko Oshima-Franco2*; Orcid: 0000-0002-4972-8444 1. Institute of Health Sciences, Paulista University (UNIP), Sorocaba, São Paulo, Brazil; [email protected] 2. Graduate Program in Pharmaceutical Sciences, University of Sorocaba (UNISO), Sorocaba, São Paulo, Brazil; [email protected], [email protected], [email protected] (*Correspondence) 3. Graduate Program in Toxicological Biochemistry, Federal University of Santa Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil; [email protected] 4. Laboratory of Neurobiology and Toxinology (Lanetox), Federal University of Pampa (UNIPAMPA), São Gabriel, Rio Grande do Sul, Brazil; [email protected] 5. Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas 13083-970, São Paulo, Brazil; [email protected] 6.
  • Production of Microbial Polysaccharides for Use in Food

    Production of Microbial Polysaccharides for Use in Food

    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/260201214 Production of microbial polysaccharides for use in food Chapter · March 2013 DOI: 10.1533/9780857093547.2.413 CITATIONS READS 21 4,237 1 author: Ioannis Giavasis University of Thessaly 39 PUBLICATIONS 588 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: Archimedes View project Bacillus toyonensis View project All content following this page was uploaded by Ioannis Giavasis on 30 April 2018. The user has requested enhancement of the downloaded file. 1 2 3 4 5 6 16 7 8 9 Production of microbial polysaccharides 10 11 for use in food 12 Ioannis Giavasis, Technological Educational Institute of Larissa, Greece 13 14 DOI: 15 16 Abstract: Microbial polysaccharides comprise a large number of versatile 17 biopolymers produced by several bacteria, yeast and fungi. Microbial fermentation has enabled the use of these ingredients in modern food and 18 delivered polysaccharides with controlled and modifiable properties, which can be 19 utilized as thickeners/viscosifiers, gelling agents, encapsulation and film-making 20 agents or stabilizers. Recently, some of these biopolymers have gained special 21 interest owing to their immunostimulating/therapeutic properties and may lead to 22 the formation of novel functional foods and nutraceuticals. This chapter describes the origin and chemical identity, the biosynthesis and production process, and the 23 properties and applications of the most important microbial polysaccharides. 24 25 Key words: biosynthesis, food biopolymers, functional foods and nutraceuticals, 26 microbial polysaccharides, structure–function relationships. 27 28 29 16.1 Introduction 30 31 Microbial polysaccharides form a large group of biopolymers synthesized 32 by many microorganisms, as they serve different purposes including cell 33 defence, attachment to surfaces and other cells, virulence expression, energy 34 reserves, or they are simply part of a complex cell wall (mainly in fungi).